Robinhood Asset Management LLC Invests $593,000 in Gilead Sciences, Inc. $GILD

Robinhood Asset Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,832 shares of the biopharmaceutical company’s stock, valued at approximately $593,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Corundum Trust Company INC acquired a new position in shares of Gilead Sciences during the third quarter worth about $26,000. Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences during the second quarter worth about $30,000. MTM Investment Management LLC grew its position in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $37,000. Finally, Millstone Evans Group LLC grew its position in shares of Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the insider owned 131,779 shares in the company, valued at $19,006,485.17. This represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer owned 179,191 shares of the company’s stock, valued at $25,844,717.93. This trade represents a 1.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 299,280 shares of company stock worth $42,820,550 over the last three months. 0.27% of the stock is owned by company insiders.

Gilead Sciences Price Performance

GILD stock opened at $140.13 on Tuesday. The company has a market capitalization of $173.93 billion, a P/E ratio of 20.70, a PEG ratio of 1.83 and a beta of 0.39. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The business has a 50 day simple moving average of $145.14 and a 200-day simple moving average of $129.84. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

Analysts Set New Price Targets

A number of brokerages have recently commented on GILD. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. HSBC upped their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Leerink Partners upped their price target on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Oppenheimer upped their price target on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.